EFTX-G12V-pTEAD

**EFTX-G12V-pTEAD** is a preclinical, EGFR-directed inverted chimeric small interfering RNA therapeutic being developed by EnFuego Therapeutics with the University of North Carolina at Chapel Hill. It covalently links a KRAS G12V-selective siRNA component and a pan-TEAD siRNA component through an endonucleolytic DNA bridge, enabling simultaneous knockdown of mutant KRAS G12V and TEAD1, TEAD2, TEAD3, and TEAD4 within the same tumor cell. The molecule is conjugated to an EGFR linear ligand to preferentially deliver payload to EGFR-expressing tumors while limiting systemic exposure. It is intended to address YAP/TAZ-TEAD pathway-mediated resistance to KRAS inhibition in KRAS G12V-mutant solid tumors.